Sollievo Pharmaceuticals
Early Stage
When Minutes Matter
Analytics
Raised: $19,830
Aggregate Commitments $
Platform
StartEngine
Start Date
08/05/2022
Close Date
11/16/2022
Min. Goal
$10,000
Max. Goal
$1,070,000
Min. Investment
$400
Security Type
Equity - Common
Funding Type
RegCF
Series
Pre-Seed
Price Per Share
$2.00
Pre-Money Valuation
$20,000,000
Rolling Commitments $
Status
Active
Reporting Date
08/18/2022
Days Remaining
90
% of Min. Goal
198%
% of Max. Goal
2%
Likelihood of Max
Avg. Daily Raise
$1,525
Momentum
Create a free account today to gain access to KingsCrowd analytics.
Location
San Juan Capistrano, California
Industry
Healthcare & Pharmaceuticals
Tech Sector
HealthTech
Distribution Model
B2B
Margin
Medium
Capital Intensity
High
Sollievo Pharmaceuticals, with a valuation of $20 million, is raising funds on StartEngine. The company has developed a fast-acting sedative in the form of an injectable benzodiazepine. The sedative, Proviza, causes rapid sedation in agitated and aggressive patients and protects healthcare staff from injuries and abuse. Proviza is highly water-soluble and brings about sedation in 5-10 minutes. Robert Schultz founded Sollievo Pharmaceuticals in February 2018. The current crowdfunding campaign has a minimum target of $10,000 and a maximum target of $1,070,000. The campaign proceeds will be used for the completion of the patient clinical trial, submission of the New Drug Application, and receiving FDA approval.
Summary Profit and Loss Statement
| Most Recent Year | Prior Year | |
|---|---|---|
|
Revenue |
$0 |
$0 |
|
COGS |
$0 |
$0 |
|
Tax |
$0 |
$0 |
| ||
| ||
|
Net Income |
$-189,478 |
$-1,164,009 |
Summary Balance Sheet
| Most Recent Year | Prior Year | |
|---|---|---|
|
Cash |
$153 |
$1,157 |
|
Accounts Receivable |
$0 |
$0 |
|
Total Assets |
$153 |
$1,157 |
|
Short-Term Debt |
$772,225 |
$655,821 |
|
Long-Term Debt |
$1,252,890 |
$1,180,819 |
|
Total Liabilities |
$2,025,115 |
$1,836,640 |
Financials as of: 08/05/2022
Create a free account today to gain access to KingsCrowd analytics.
Upgrade to gain access
Pay Monthly
Annually (Save 17%)
-
$12.42 /month
billed annually - Free portfolio tracking and KingsCrowd's quantitative ratings on all raises.
- Plan Includes:
- Everything in Free, plus
- Company specific
KingsCrowd ratings (excluding risk)
- Advanced company search ( with ratings)
- Markets page filters and historical industry data
- Get Edge Annual
Edge
-
$41.58 /month
billed annually - Full site access including KingsCrowd's qualitative analyst reports.
- Plan Includes:
- Everything in Edge, plus
- Full access to detailed Analyst Reports (e.g. Top Deal, Deal to Watch, Neutral, and Underweight)
- Search and filter based on Analyst Reports
- In-depth risk ratings for every raise
- Get Edge Pro Annual
Edge Pro
Already a member? Log in here.
Ratings 
